Menu Content/Inhalt
Search  

PRESS RELEASES


   Order     Display # 
Date Item Title
04-Feb-2010 Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
13-Oct-2009 Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer
11-May-2009 Debiopharm and Mepha sign distribution agreement for Pamorelin® LA 1-3- and 6-month formulations - a new treatment for prostate cancer patients in Switzerland -
31-Mar-2009 Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin Pamoate
14-Nov-2008 Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer
25-Sep-2008 Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients
12-Feb-2008 Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer
31-Oct-2007 Ipsen and Debiopharm extend their Agreement for the Exclusive Commercialization of Decapeptyl®
11-May-2005 Debiopharm announces marketing and supply agreement for Trelstar® in Canada
20-Dec-2004 Debiopharm S.A. and Rowfarma S. de R.L. de C.V. enter into an Exclusive Licensing Agreement in Mexico for two approved Urology and Endometriosis Products - Decapeptyl® Depot and Decapeptyl® LA
29-Sep-2004 Debiopharm and Watson Pharmaceuticals enter into an Exclusive Licensing Agreement for two approved urology products - Trelstar® DEPOT and Trelstar® LA
23-Mar-2004 Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany
02-Dec-2003 Debiopharm S.A. seeks New Partner to Commercialise Trelstar® (Triptorelin Pamoate) in the US, Canada and Mexico for the Treatment of Prostate Cancer
05-Jul-2001 Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use
 
< Prev 1 Next >
Results 1 - 14 of 14